Find Reliable Skins Treatment at Dermatology Specialists of Charlotte
Phase lllb clinical trial, being conducted by Janssen Research and Development, evaluating Guselkumab (Tremfya) for the treatment of moderate-severe plaque or scalp psoriasis in skin of color.
This trial consists of a 48-weeks blinded treatment period and a 100-week long term extension. During the primary 16-weeks of the trial, there will be a placebo cohort. After this, all participants will receive guselkumab 100mg Q8wks for the remainder of the treatment period and long-term extension.
Previous trials for Tremfya included 77-93% white participants. The trial will specifically enroll patients who self-identify as a person of color. The main study requirements are listed below.
If a subject qualifies for the trial, all medical care related to the trial and the study medication, Tremfya, will be supplied as no cost. Subject will also be paid a stipend for their time and travel expenses.